Use of mycophenolate mofetil in the treatment of primary sclerosing cholangitis [9]

Journal of Clinical Gastroenterology

Volumn 36, Issue 1, 2003, Pages 86-

  Lankarani, Kamran Bagheri ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; URSODEOXYCHOLIC ACID;

ADULT; CASE REPORT; DIARRHEA; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; HUMAN; LETTER; LIVER TRANSPLANTATION; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; ULCERATIVE COLITIS;

EID: 0037213972     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200301000-00029     Document Type: Letter

References (5)

1. Lee YM, Kaplan MM, Practice Guideline Committees of the ACG. Management of primary sclerosing cholangitis. Am J Gastroenterol 2002;97:528-34.
2. Jones GA, ten Kate FJW, ter Borg F, et al. Combination therapy with mycophenolate mofetil and ursodioxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:1165-9.
3. Altschuler EL, Mycophenolate mofetil for primary biliary cirrhosis and sclerosing cholangitis? Nephrol Dial Transplant 1999;14:798-9.
4. Smak Gregoor PJ, Van Gelder T, Weimar W. Mycophenolate mofetil, cell cept: A new immunosuppressive drug with great potential in internal medicine. Neth J Med 2000;57:233-46.
5. Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357-9.